GILD Latest Press Releases

-- January 6, 2026 --

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD Delivery Technology to Gilead's Drug Candidate Business Wire 7:00 AM

-- December 19, 2025 --

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans Business Wire 2:21 PM

-- December 18, 2025 --

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Business Wire 8:30 AM

-- December 15, 2025 --

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial Business Wire 8:30 AM

-- December 12, 2025 --

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era Globe Newswire 10:31 AM

-- December 9, 2025 --

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer Business Wire 8:30 AM

-- December 7, 2025 --

Yescarta Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025 Business Wire 8:00 AM

-- December 6, 2025 --

Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025 Business Wire 2:00 PM

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma Business Wire 2:00 PM

-- November 24, 2025 --

Gilead Foundation Commits Over $3 Million to Address Food Insecurity Business Wire 8:30 AM

-- November 20, 2025 --

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs PRNewswire 7:13 AM

-- November 18, 2025 --

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa Business Wire 5:00 AM

-- November 13, 2025 --

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial Business Wire 8:30 AM

-- November 7, 2025 --

Gilead Provides Update on Phase 3 ASCENT-07 Study Business Wire 8:30 AM

Gilead's Livdelzi Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression Business Wire 8:00 AM

-- November 4, 2025 --

Gilead Sciences to Present at Upcoming Investor Conferences Business Wire 4:05 PM

-- November 3, 2025 --

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 Business Wire 9:10 AM

-- October 31, 2025 --

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo (Lenacapavir) Business Wire 8:00 AM

-- October 30, 2025 --

Gilead Sciences Announces Third Quarter 2025 Financial Results Business Wire 4:02 PM

-- October 23, 2025 --

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta Business Wire 8:00 AM

-- October 21, 2025 --

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners PRNewswire 8:05 AM

-- October 19, 2025 --

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025 Business Wire 8:30 AM

Trodelvy Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study Business Wire 2:30 AM

-- October 15, 2025 --

Gilead Presents New HIV Research Data at EACS 2025 - Driving Scientific Innovation in Treatment and Prevention Business Wire 3:30 AM

-- October 13, 2025 --

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 Business Wire 8:30 AM

-- October 9, 2025 --

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025 Business Wire 4:05 PM

-- September 25, 2025 --

Gilead Foundation Grants $6.5 Million in Commitment to STEM Education Business Wire 8:00 AM

-- September 22, 2025 --

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline Business Wire 7:00 AM

-- September 4, 2025 --

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries Business Wire 2:15 PM

Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV Business Wire 8:30 AM

-- September 3, 2025 --

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy Business Wire 11:30 AM

-- August 26, 2025 --

European Commission Authorizes Twice-Yearly Yeytuo (Lenacapavir) for HIV Prevention Business Wire 3:00 AM

-- August 21, 2025 --

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform Business Wire 8:30 AM

-- August 20, 2025 --

Gilead Sciences to Present at Upcoming Investor Conferences Business Wire 4:05 PM